Clinical Trials Logo

Clinical Trial Summary

Cryptococcus neoformans and C. gatti are important causes of central nervous system (CNS) infections with significant mortality, remaining a great public health challenge worldwide. Commonly seen as an opportunistic infection in adults with HIV/AIDS, cryptococcal meningitis (CM) accounts for 15% of HIV-related mortality globally [1]. In addition, a growing number of non-HIV CM patients have been observed in recent years with fatality approaching 30% in some areas [2,3]. It occurs in both those with natural or iatrogenic immunosuppression, as well as the apparently immunocompetent individuals. Approximately 65-70% of non-HIV CM patients were without any predisposing factors, particularly in the East Asia [4,5]. With the increasing number of hematopoietic stem cell transplantation, solid organ transplantation recipients and administration of immunosuppressive and corticosteroids agents, this illness will assume even greater public health significance. Current Infectious Disease Society of America (IDSA) guideline suggest the use of combination antifungal therapy: normal dose amphotericin (0.7-1mg/kg/day) combined with flucytosine for a minimum of 4 weeks, followed by fluconazole (600-800 mg/day) for a minimum of 10 weeks in total for HIV patients [6]. However, for non-HIV and immunocompetent patients, the treatment remains controversial. IDSA guideline recommended that the treatment of non-HIV patients could refer to the treatment of HIV patients. That is, amphotericin B combined with flucytosine is still administered in the induction period. However, as amphotericin B have nonspecific effect on ergosterol, it has strong side effects (hepatorenal toxicity, electrolyte disorder, anemia, ventricular fibrillation, etc.). Therefore, the dose of amphotericin B may not be appropriate for Asian patients due to the different drug metabolism and pharmacokinetic. In the prospective studies of Bennett[7] and Dismuke[8], low dose amphotericin B (0.3 mg/kg/d) combined with flucytosine achieved response rates of 66% and 85% at 6 weeks, respectively. A similar conclusion was also extracted from a large multicenter retrospective study that low dose amphotericin B (<0.7 mg/kg/d) combined with flucytosine for a minimum of 2 weeks, followed by fluconazole could achieve a response rate of 84%, indicating that the efficacy of low dose amphotericin B (< 0.7 mg/kg/d) may be equivalent with normal dose in non-HIV patients. Therefore, we plan to conduct a prospective, multicenter, open-label randomized controlled study to compare the efficacy and safety of normal dose amphotericin B (0.7 mg/kg/ d) and low dose amphotericin B (0.5 mg/kg/d) in the initial antifungal treatment for non-HIV cryptococcal meningitis patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06178627
Study type Interventional
Source Huashan Hospital
Contact
Status Enrolling by invitation
Phase Phase 4
Start date August 13, 2023
Completion date August 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT01589289 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Phase 3
Completed NCT00976040 - Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis Phase 4
Completed NCT04031833 - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) Phase 1/Phase 2
Completed NCT00830856 - Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa N/A
Completed NCT04532463 - Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Completed NCT02098525 - Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy N/A
Completed NCT01075152 - Cryptococcal Optimal ART Timing Trial Phase 4
Active, not recruiting NCT01715922 - Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Phase 2/Phase 3
Completed NCT00145249 - Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis Phase 2
Completed NCT01802385 - Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Phase 3
Terminated NCT00324025 - Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Phase 2
Completed NCT02955862 - Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report Phase 1
Recruiting NCT03945448 - Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia Phase 2/Phase 3
Active, not recruiting NCT02624453 - Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS N/A
Recruiting NCT00867269 - Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Completed NCT01535469 - Operational Research for Cryptococcal Antigen Screening Phase 4
Active, not recruiting NCT04072640 - Three Induction Treatments on Cryptococcal Meningitis Early Phase 1
Not yet recruiting NCT05541107 - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 Phase 3
Not yet recruiting NCT02686853 - Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Phase 4
Not yet recruiting NCT04140461 - AmB Dose for Cryptococcal Meningitis Phase 3